Weight-Loss Injections Ozempic & Zepbound Face Over 2,000 Lawsuits As Patients Allege Vision Loss, Gallbladder Disease & Vomiting

Weight-Loss Injections Ozempic & Zepbound Face Over 2,000 Lawsuits As Patients Allege Vision Loss, Gallbladder Disease & Vomiting
More than 2,000 lawsuits have been filed in the United States against the makers of Ozempic and Zepbound, with patients alleging life-threatening side effects linked to the popular diabetes and weight-loss drugs.
The consolidated litigation, based in Pennsylvania federal court, is now in the discovery phase. In February 2024, the Judicial Panel on Multidistrict Litigation grouped the cases into MDL No. 3094, and by August 2025 legal trackers reported over 2,000 active cases.
Plaintiffs claim Novo Nordisk and Eli Lilly failed to adequately warn about risks. Central to the lawsuits are allegations that patients developed gastroparesis, or stomach paralysis. Other reported side effects include intestinal obstruction, ileus, vomiting, gallbladder disease, and vision loss.
Attention has increasingly turned to Zepbound, approved in 2023, with the FDA updating its label in 2025 to include ileus. Both companies deny wrongdoing, maintaining that product information complies with federal standards and risks are clearly outlined.
What are your thoughts on these shocking claims?
Previous Article
Next Article
Soulja Boy Survives California Mudslide Accident: “I’m just thankful to be alive”
Donald Glover In The Running For “Willie Wonka & The Chocolate Factory” PrequelÂ
[LISTEN] Mimi Faust’s Boyfriend Nikko Releases ‘Shower Rod’ Song
Floyd Mayweather & Ray J Spend $50K At ‘Diamonds of Atlanta’ Strip Club
Time Flies When You’re Pregnant, Amber Rose Unveils Belly At 28 Weeks
EXCLUSIVE: Tiffany Haddish Praises Ex Husband In New Recording, Contradicting Claims in Memoir [AUDIO]
Waka Flocka (Sorta) Agrees With Stacey Dash: Why the f**k do we have BET? [VIDEO]
Jussie Smollett Allegedly Bought Drug Molly From Nigerian Brothers + Apologized To ‘Empire’ Cast, Maintains His InnocenceÂ